Scopus BioPharma Inc.
SCPS · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,993 | $1,609 | $746 | $917 |
| G&A Expenses | $936 | $1,071 | $1,090 | $981 |
| SG&A Expenses | $936 | $1,071 | $1,090 | $981 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,929 | $2,680 | $1,836 | $1,899 |
| Operating Income | -$2,929 | $0 | -$1,836 | -$1,899 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$2,680 | $0 | $0 |
| Pre-Tax Income | -$2,929 | -$2,680 | -$1,836 | -$1,899 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,617 | -$2,450 | -$1,731 | -$1,899 |
| % Margin | – | – | – | – |
| EPS | -0.066 | -0.081 | -0.082 | -0.09 |
| % Growth | 18.5% | 1.7% | 8.8% | – |
| EPS Diluted | -0.066 | -0.081 | -0.082 | -0.09 |
| Weighted Avg Shares Out | 39,743 | 30,370 | 21,094 | 21,094 |
| Weighted Avg Shares Out Dil | 39,743 | 30,370 | 21,094 | 21,094 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2,929 | -$2,679 | -$1,836 | -$1,898 |
| % Margin | – | – | – | – |